Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member

Search

1736889

registered interest
date	24/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Plastics
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to reduce the number of single-use items used by the National Health Service.
tabling member constituency	Cannock Chase
tabling member printed	Josh Newbury
uin	11075
answer	answer is ministerial correction date of answer 29/10/2024 answer text <p>As set out in the Delivering a Net Zero National Health Service report, published in October 2020, the NHS is committed to reducing its environmental impact, including by increasing the reuse and recycling of medical equipment. This report is available at the following link:</p><p><a href="https://www.england.nhs.uk/greenernhs/wp-content/uploads/sites/51/2022/07/B1728-delivering-a-net-zero-nhs-july-2022.pdf" target="_blank">https://www.england.nhs.uk/greenernhs/wp-content/uploads/sites/51/2022/07/B1728-delivering-a-net-zero-nhs-july-2022.pdf</a></p><p>In October 2024, the Government published the Design for Life roadmap, a new strategy to transition away from all avoidable single-use medical technology products towards a functioning circular system by 2045. This roadmap is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/design-for-life-roadmap" target="_blank">https://www.gov.uk/government/publications/design-for-life-roadmap</a></p><p>The programme is expected to support the NHS by improving resilience, reducing waste, delivering cost savings, and achieving the NHS commitment to be net zero by 2045. The Design for Life roadmap provides examples of where NHS organisations are already achieving cost, waste, and carbon savings through reusing, remanufacturing, and recycling medical devices and equipment, in line with their local Green Plans.</p><p>In addition, NHS England collaborates with NHS Supply Chain to increase the availability of reusable products, and supports local NHS organisations to use more reusable medical devices and products, where it is safe to do so. For example, NHS England supported the Royal Surgical Colleges to develop the evidence-based Green Theatre Checklist to encourage sustainable theatre approaches, including promoting the use of reusable or remanufactured equipment, where appropriate. Further information on the checklist is available at the following link:</p><p><a href="https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.rcsed.ac.uk%2Fprofessional-support-development-resources%2Fenvironmental-sustainability-and-surgery%2Fgreen-theatre-checklist&amp;data=05%7C02%7Cpeter.cockett%40dhsc.gov.uk%7Cf01efded06ed487f31c008dcf771769f%7C61278c3091a84c318c1fef4de8973a1c%7C1%7C0%7C638657317044844782%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&amp;sdata=0hYqHXF9AWLMPThOJQOk8sKp18XtE85BVjBeaVrc2qE%3D&amp;reserved=0" target="_blank">https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.rcsed.ac.uk%2Fprofessional-support-development-resources%2Fenvironmental-sustainability-and-surgery%2Fgreen-theatre-</a></p><p>Additionally, NHS England is supporting innovation through the Small Business Research Initiative Healthcare programme, which has funded a project to support reuse of surgical textiles, with further information available at the following link:</p><p><a href="https://sbrihealthcare.co.uk/impact-case-studies/case-studies/revolution-zero" target="_blank">https://sbrihealthcare.co.uk/impact-case-studies/case-studies/revolution-zero</a></p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 29/10/2024 17:13:37 answering member 4444 label Biography information for Karin Smyth
tabling member	5034

1736894

registered interest
date	24/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Myasthenia Gravis: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential merits of making (a) rozanolixizumab, (b) zilucoplan and (c) efgartigimod available to NHS patients with myasthenia gravis (MG); and what (i) representations his Department has received from and (ii) meetings his Department has had with MG patients on that matter.
tabling member constituency	Basildon and Billericay
tabling member printed	Mr Richard Holden
uin	11055
answer	answer is ministerial correction date of answer 29/10/2024 answer text <p>The Department has made no such assessment. The National Institute for Health and Care Excellence (NICE) makes evidence-based recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. The NICE is currently evaluating rozanolixizumab, zilucoplan, and efgartigimod within their licensed indications for the treatment of myasthenia gravis, and has not yet published final guidance.</p><p>The Department has received correspondence letters from constituents via their Member of Parliament regarding myasthenia gravis and the treatment for this condition, but there have not been any recent meetings between Ministers and patients with this condition.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 29/10/2024 16:51:04 answering member 4444 label Biography information for Karin Smyth
tabling member	4813 label Biography information for Mr Richard Holden

1736913

registered interest
date	24/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Chronic Fatigue Syndrome and Long Covid
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made with the Chancellor of the Exchequer of the potential impact of (a) ME and (b) long covid on economic growth.
tabling member constituency	Wells and Mendip Hills
tabling member printed	Tessa Munt
uin	10994
answer	answer is ministerial correction date of answer 30/10/2024 answer text <p>No assessment has been made on the impact of myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), and long COVID on economic growth. However, the Government recognises that long-term sickness continues to be the most common reason for economic inactivity among the working age population. As part of the Get Britain Working plan, more disabled people and those with health conditions will be supported to enter and stay in work, by devolving more power to local areas so they can shape a joined-up work, health, and skills offer that suits the needs of the people they serve.</p><p>The Government has established a Growth Mission Board focused squarely on reviving economic growth, and has established a new Growth Delivery Unit in HM Treasury to track and support delivery of key growth priorities.</p><p>The final ME/CFS delivery plan is a priority for the Department, and it is our intention to publish a response summary later this autumn. We cannot comment on the exact content of the final delivery plan at this time, but it will be shaped by the consultation responses, along with continued close engagement with stakeholders, with three broad themes of attitudes and education, research, and living with ME/CFS. We aim to publish this in the winter of 2024/25.</p><p>The Department funds ME/CFS research through the National Institute for Health and Care Research (NIHR). The NIHR and the Medical Research Council (MRC) are committed to funding high-quality research to understand the causes, consequences, and treatment of ME/CFS, and are actively exploring next steps for research in this area. The NIHR welcomes funding applications for research into any aspect of human health, including ME/CFS.</p><p>Ring-fencing funding for ME/CFS has been considered and discussed with the community during the development of the Interim Delivery Plan for ME/CFS, as well as the recent roundtables on ME/CFS and Long COVID. Ring-fencing is not usual practice for research funders as applications in all areas compete for the funding available. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. In all areas, the amount of NIHR funding depends on the volume and quality of scientific activity. Funding for high quality research is available through NIHR programmes, and there is support available for researchers to successfully apply for these awards.</p><p>Over the last five years, the NIHR has invested over £3.6 million in research programme funding for ME/CFS. This includes over £1.5 million to the DecodeME study, co-funded with the MRC, which aims to understand if there is a genetic component to the condition, and in doing so increase our understanding of ME/CFS to support the development of diagnostic tests and targeted treatments.</p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne grouped question UIN 10995 10996 question first answered 30/10/2024 16:30:29 answering member 1506 label Biography information for Andrew Gwynne previous answer version 13733 answering member constituency Gorton and Denton answering member printed Andrew Gwynne answering member 1506 label Biography information for Andrew Gwynne
tabling member	4089 label Biography information for Tessa Munt

1736914

registered interest
date	24/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Chronic Fatigue Syndrome and Long Covid
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether the delivery plan for ME/CFS will include measures to improve the safety of NHS care for patients with ME.
tabling member constituency	Wells and Mendip Hills
tabling member printed	Tessa Munt
uin	10995
answer	answer is ministerial correction date of answer 30/10/2024 answer text <p>No assessment has been made on the impact of myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), and long COVID on economic growth. However, the Government recognises that long-term sickness continues to be the most common reason for economic inactivity among the working age population. As part of the Get Britain Working plan, more disabled people and those with health conditions will be supported to enter and stay in work, by devolving more power to local areas so they can shape a joined-up work, health, and skills offer that suits the needs of the people they serve.</p><p>The Government has established a Growth Mission Board focused squarely on reviving economic growth, and has established a new Growth Delivery Unit in HM Treasury to track and support delivery of key growth priorities.</p><p>The final ME/CFS delivery plan is a priority for the Department, and it is our intention to publish a response summary later this autumn. We cannot comment on the exact content of the final delivery plan at this time, but it will be shaped by the consultation responses, along with continued close engagement with stakeholders, with three broad themes of attitudes and education, research, and living with ME/CFS. We aim to publish this in the winter of 2024/25.</p><p>The Department funds ME/CFS research through the National Institute for Health and Care Research (NIHR). The NIHR and the Medical Research Council (MRC) are committed to funding high-quality research to understand the causes, consequences, and treatment of ME/CFS, and are actively exploring next steps for research in this area. The NIHR welcomes funding applications for research into any aspect of human health, including ME/CFS.</p><p>Ring-fencing funding for ME/CFS has been considered and discussed with the community during the development of the Interim Delivery Plan for ME/CFS, as well as the recent roundtables on ME/CFS and Long COVID. Ring-fencing is not usual practice for research funders as applications in all areas compete for the funding available. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. In all areas, the amount of NIHR funding depends on the volume and quality of scientific activity. Funding for high quality research is available through NIHR programmes, and there is support available for researchers to successfully apply for these awards.</p><p>Over the last five years, the NIHR has invested over £3.6 million in research programme funding for ME/CFS. This includes over £1.5 million to the DecodeME study, co-funded with the MRC, which aims to understand if there is a genetic component to the condition, and in doing so increase our understanding of ME/CFS to support the development of diagnostic tests and targeted treatments.</p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne grouped question UIN 10994 10996 question first answered 30/10/2024 16:30:29 answering member 1506 label Biography information for Andrew Gwynne previous answer version 13735 answering member constituency Gorton and Denton answering member printed Andrew Gwynne answering member 1506 label Biography information for Andrew Gwynne
tabling member	4089 label Biography information for Tessa Munt

1736915

registered interest
date	24/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Chronic Fatigue Syndrome: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of ring-fencing biomedical research funding for ME.
tabling member constituency	Wells and Mendip Hills
tabling member printed	Tessa Munt
uin	10996
answer	answer is ministerial correction date of answer 30/10/2024 answer text <p>No assessment has been made on the impact of myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), and long COVID on economic growth. However, the Government recognises that long-term sickness continues to be the most common reason for economic inactivity among the working age population. As part of the Get Britain Working plan, more disabled people and those with health conditions will be supported to enter and stay in work, by devolving more power to local areas so they can shape a joined-up work, health, and skills offer that suits the needs of the people they serve.</p><p>The Government has established a Growth Mission Board focused squarely on reviving economic growth, and has established a new Growth Delivery Unit in HM Treasury to track and support delivery of key growth priorities.</p><p>The final ME/CFS delivery plan is a priority for the Department, and it is our intention to publish a response summary later this autumn. We cannot comment on the exact content of the final delivery plan at this time, but it will be shaped by the consultation responses, along with continued close engagement with stakeholders, with three broad themes of attitudes and education, research, and living with ME/CFS. We aim to publish this in the winter of 2024/25.</p><p>The Department funds ME/CFS research through the National Institute for Health and Care Research (NIHR). The NIHR and the Medical Research Council (MRC) are committed to funding high-quality research to understand the causes, consequences, and treatment of ME/CFS, and are actively exploring next steps for research in this area. The NIHR welcomes funding applications for research into any aspect of human health, including ME/CFS.</p><p>Ring-fencing funding for ME/CFS has been considered and discussed with the community during the development of the Interim Delivery Plan for ME/CFS, as well as the recent roundtables on ME/CFS and Long COVID. Ring-fencing is not usual practice for research funders as applications in all areas compete for the funding available. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. In all areas, the amount of NIHR funding depends on the volume and quality of scientific activity. Funding for high quality research is available through NIHR programmes, and there is support available for researchers to successfully apply for these awards.</p><p>Over the last five years, the NIHR has invested over £3.6 million in research programme funding for ME/CFS. This includes over £1.5 million to the DecodeME study, co-funded with the MRC, which aims to understand if there is a genetic component to the condition, and in doing so increase our understanding of ME/CFS to support the development of diagnostic tests and targeted treatments.</p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne grouped question UIN 10994 10995 question first answered 30/10/2024 16:30:29 answering member 1506 label Biography information for Andrew Gwynne previous answer version 13734 answering member constituency Gorton and Denton answering member printed Andrew Gwynne answering member 1506 label Biography information for Andrew Gwynne
tabling member	4089 label Biography information for Tessa Munt

1736946

registered interest
date	24/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescriptions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress his Department has made on the implementation of the recommendations of his Department's report entitled Good for you, good for us, good for everybody: A plan to reduce overprescribing to make patient care better and safer, support the NHS, and reduce carbon emissions, published on 22 September 2021.
tabling member constituency	Rotherham
tabling member printed	Sarah Champion
uin	11003
answer	answer is ministerial correction date of answer 29/10/2024 answer text <p>I refer the Hon. Member to the answer I gave on 9 September 2024 to Question <a href="https://questions-statements.parliament.uk/written-questions/detail/2024-08-30/2902" target="_blank">2902</a>.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 29/10/2024 17:09:18 answering member 4444 label Biography information for Karin Smyth
tabling member	4267 label Biography information for Sarah Champion

1736963

registered interest
date	24/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dermatology: Waiting Lists
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce dermatology waiting times.
tabling member constituency	Newbury
tabling member printed	Mr Lee Dillon
uin	11131
answer	answer is ministerial correction date of answer 29/10/2024 answer text <p>Tackling waiting lists is a key part of our Health Mission. We will deliver an extra 40,000 operations, scans, and appointments, including dermatology appointments, each week, as a first step in our commitment to ensuring that patients can expect to be treated within 18 weeks.</p><p>We will be supporting National Health Service trusts to deliver these through innovation, sharing best practice to increase productivity and efficiency, and ensuring the best value is delivered.</p><p>The Government is committed to putting patients first. This means making sure that patients across all specialties, including dermatology, are seen on time, and ensuring that people have the best possible experience during their care.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 29/10/2024 16:57:32 answering member 4444 label Biography information for Karin Smyth
tabling member	5310

1736964

registered interest
date	24/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dermatology: Waiting Lists
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential impact of waiting times from GP referral to first appointment with dermatology clinic on patients; and what data his Department holds on average such waiting times (a) for NHS Buckinghamshire, Oxfordshire and Berkshire West ICB and (b) nationally.
tabling member constituency	Newbury
tabling member printed	Mr Lee Dillon
uin	11132
answer	answer is ministerial correction date of answer 29/10/2024 answer text <p>The Government is committed to putting patients first. This means making sure that patients are seen on time and ensuring that people have the best possible experience during their care, including for dermatology.</p><p>Whilst no formal assessment has been made of the potential impact of waiting times from general practice (GP) referral to first appointment with a dermatology clinic on patients, dermatology services are being transformed to make sure that patients are seen on time. NHS England’s Getting It Right First Time (GIRFT) programme is working with National Health Service trusts to deliver rapid clinical transformation, with the aim of reducing the numbers of patients waiting more than 52 weeks. The work brings together clinicians and operational teams to work collectively to transform patient pathways, reduce unnecessary appointments, and improve access and waiting times for patients.</p><p>A clinical transformation group for dermatology was established in summer 2023, focusing on sharing and learning from best practice. Topics for collaboration have included innovative clinic models, for instance super clinics, best practice in the use of technology for telemedicine, best practice in reducing Did Not Attends, reducing unnecessary follow ups through Patient Initiated Follow Up, the role of artificial intelligence, how to develop nurses into advanced roles, and factors to help motivate and retain staff.</p><p>GIRFT is also planning a programme to support primary care colleagues, offering training for new staff to recognise harmless skin lesions, like moles and warts, with the aim of reducing unnecessary referrals to hospital and freeing up capacity for other patients on the waiting list.</p><p>Unpublished management information, as of 29 September 2024, from NHS England gives the average wait time for those waiting for first activity on a dermatology pathway of 15.4 weeks for the Buckinghamshire, Oxfordshire and Berkshire West Integrated Care Board, compared to 13.9 across the whole of England.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 29/10/2024 17:17:04 answering member 4444 label Biography information for Karin Smyth
tabling member	5310

1736965

registered interest
date	24/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breastfeeding: Telephone Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make funding for the National Breastfeeding Helpline's overnight service permanent.
tabling member constituency	Newbury
tabling member printed	Mr Lee Dillon
uin	11133
answer	answer is ministerial correction date of answer 30/10/2024 answer text <p>Breastfeeding has significant benefits for both mothers and babies and it’s important that families are supported to meet their infant feeding goals.</p><p>The Family Hubs and Start for Life programme has funded the expansion of the National Breastfeeding Helpline, helping families across the country to access virtual breastfeeding support. This includes a pilot of the night-time service from March 2024, ensuring help is available at all times of the day and night, every day of the year.</p><p>The night service pilot is currently funded to run until the end of March 2025, and we will independently evaluate the pilot to inform future decisions on funding for this service.</p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne question first answered 30/10/2024 14:13:16 answering member 1506 label Biography information for Andrew Gwynne
tabling member	5310

1736993

registered interest
date	24/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	General Practitioners: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how much (a) funding and (b) other resources his Department is providing to GP practices to help meet the demand for appointments in the (a) 2024-25 and (b) 2025-26 financial year.
tabling member constituency	Ashfield
tabling member printed	Lee Anderson
uin	11046
answer	answer is ministerial correction date of answer 31/10/2024 answer text <p>We hugely value the critical role that general practitioners (GPs) play, and we are determined to address the issues they face by shifting the focus of the National Health Service beyond hospitals and into the community. GPs and primary care have been receiving a smaller proportion of NHS resources over time, and we’re committed to reversing that.</p><p>On 28 February 2024, NHS England published details of the changes to the GP contract for 2024/25, including an overall increase in funding of £259 million, taking overall contract investment to £11,864 million in 2024/25. The 2024/25 contract at that point included a 2% planning assumption for pay, which was used to uplift the GP contract from 1 April 2024. We turned to the independent pay review body, the Doctors' and Dentists' Remuneration Board (DDRB), for a recommendation on pay for 2024/25.</p><p>We have accepted the DDRB’s recommendations in full and, following consultation with the British Medical Association, we uplifted the pay element of the GP contract by 6% on a consolidated basis, an increase of 4% on top of the 2% interim uplift in April, to provide practices with funding to uplift GP partners, salaried GPs, and other salaried staff pay by 6%. The global sum element of the contract has been increased by 7.4% to fund the 6% increase in pay.</p><p>Departmental expenditure limits for 2025/26 will be set alongside the Budget in October. The overall GP contract investment in 2025/26 will be determined afterwards.</p> answering member constituency Aberafan Maesteg answering member printed Stephen Kinnock question first answered 31/10/2024 11:32:38 answering member 4359 label Biography information for Stephen Kinnock
tabling member	4743 label Biography information for Lee Anderson